Cefuroxime Axetil USP
MENAT® 125 : Each film coated tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 125mg.
MENAT® 250 : Each film coated tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 205mg.
MENAT® Powder for Suspension : Each film coated tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 125mg.
MENAT® (Cefuroxime Axetil) is an oral pro drug of the bactericidal cephalosporin antibiotic Cefuroxime which is active against a wide range of Gram-positive and Gram-negative organisms including few beta-lactamase producing strains. It is indicated for the treatment of infections caused by sensitive bacteria.
Menat is indicated in the treatment of
Upper respiratory tract infections: Ear, nose, throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis.
Lower respiratory tract infections: Acute and chronic bronchitis and pneumonia.
Genito-urinary tract infections: pyelonephritis, cystitis and urethritis, gonorrhea, aute uncomplicated gonococcal urethritis and cervicitis.
Skin and soft tissue infections: Furunculosis, pyoderma and impetigo.
Lyme disease: Erythema marginatum.
Infection: Dosage time Duration
Adolescents & Adults:
(13 years & Above) (May be administered without regard to meals)
Pharyngitis or tonsillitis 250mg twice daily 10 days
Acute bacterial maxillary
sinusitis 250mg twice daily 10 days
Acute bacterial exacerbations
of chronic bronchitis 250-500mg twice daily 10 days
Secondary bacterial infections
of acute bronchitis 25-500mg twice daily 10 days
Uncomplicated skin &
skin-structure infections 250-500mg twice daily 10 days
delays tract infections 125-250mg twice daily 10 days
Uncomplicated gonorrhea 1000mg single dose
Early Lyme disease 500mg twice daily 20 days
Paediatric patients (3 months to 12 years)
(Paediatric patient should take the drug with food)
Pharyngitis or Tonsillitis 125mg twice daily 10 days
Acute otitis media 250mg twice daily 10 days
Acute bacterial maxillary sinusitis 250 mg twice daily
Patients with known allergy to cephalosporins & pseudomembranous colitis are contraindicated.
MENAT® (Cefuroxime Axetil) should be given with care to patients receiving concurrent treatment with potent diuretics & who have history of colitis.
Pregnancy: while all antibiotics should be avoided in the first trimester if possible However, Cefuroxime Axetil has been safely used in later pregnancy to treat urinary and other infections. Lactating Mothers: Cefuroxime is excreted into the milk in small quantities However, the possibility of sensitizing the infant should be kept in mind.
Generally Cefuroxime is well tolerated. However, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. As with other broad-spectrum antibiotics, prolonged administration of Cefuroxime Axetil may result in overgrowth of nonsusceptible microorganisms. Rarely (<0.2%) renal dysfunction, anaphylaxis, angiodema, pruritis, rash and serum sickness like urticaria may appear.
Concomitant administration of probenecid with Cefuroxime increase the area under the serum concentration versus time curve by 50%. Drug that reduces gastric acidity may result in a lower bioavailability of Cefuroxime and tend to cancel the effect of post prandial absorption.
Signs and symptoms: Over dosage of Cefuroxime can cause cerebral irritation leading to convulsions.
Management: Serum levels of Cefuroxime can be reduced by haemo dialysis or peritoneal dialysis
Capsule: Store at room termerature
Suspension: Prior to reconstitution, store at room temperature. After reconstitution the suspension may be kept for 14 days under refrigeration or 7 days at room temperature, without significant loss of potency.
MENAT® 125 Tablet: Each box contains 2 Alu-Alu blister stips of 4 tablets.
MENAT® 250 Tablet: Each box contains 2 Alu-Alu blister stips of 4 tablets.
MENAT® Suspensions: Bottle containing dry powder for preparation of 70ml suspension.